Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

This study is specifically for adults between 18 and 59 years old who have just been diagnosed with a type of blood cancer called Acute Myeloid Leukemia (AML). It's important that your AML is considered 'high-risk' by doctors and that you haven't started any treatment for it yet. Some specific types of AML, or if you have certain changes in your genes, mean you wouldn't be able to join.

Also, if you've had a lot of certain types of chemotherapy in the past, or if your doctors consider your general health to be severely poor, this study might not be suitable for you. The study aims to find treatments for newly diagnosed, high-risk AML, so these are key factors in deciding who can take part.

If you join this study, you'll be randomly assigned to one of five treatment groups, like flipping a coin to decide. Each group receives a different combination of medicines. These medicines will be given intravenously (into a vein), subcutaneously (under the skin), or orally (by mouth) over cycles, typically lasting about 28 days each. You might have one or two cycles of treatment in the study.

Throughout the study, you'll have regular hospital visits: You'll have blood tests, bone marrow samples taken (this is a procedure where a small sample of fluid and tissue is taken from inside your bone), and heart scans (like an echocardiogram or MUGA scan) to check how you're doing. These tests help doctors understand how well the treatment is working and if there are any side effects. The total duration of your active treatment within the study will depend on the assigned group and your response to treatment.